Definitive Healthcare (NASDAQ:DH) Earns Underperform Rating from Bank of America

Definitive Healthcare (NASDAQ:DH)‘s stock had its “underperform” rating reiterated by investment analysts at Bank of America in a research note issued to investors on Monday,Benzinga reports. They presently have a $0.70 price objective on the stock. Bank of America‘s target price would indicate a potential upside of 6.06% from the company’s current price.

Several other brokerages have also weighed in on DH. Zacks Research raised Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Wednesday, June 3rd. Wall Street Zen raised Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Robert W. Baird set a $1.10 target price on shares of Definitive Healthcare in a research report on Friday, May 8th. Finally, Barclays cut their price target on shares of Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating on the stock in a report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $2.47.

Definitive Healthcare Price Performance

DH opened at $0.66 on Monday. The company’s 50 day simple moving average is $0.89 and its 200 day simple moving average is $1.49. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.75 and a current ratio of 1.75. Definitive Healthcare has a 1 year low of $0.62 and a 1 year high of $4.70. The stock has a market capitalization of $69.64 million, a PE ratio of -0.41, a P/E/G ratio of 8.88 and a beta of 1.33.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. The firm had revenue of $55.93 million during the quarter, compared to analyst estimates of $55.02 million. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. As a group, sell-side analysts expect that Definitive Healthcare will post 0.05 EPS for the current year.

Institutional Investors Weigh In On Definitive Healthcare

Several hedge funds have recently modified their holdings of DH. Goldman Sachs Group Inc. boosted its holdings in Definitive Healthcare by 564.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after acquiring an additional 7,404,363 shares during the period. Arrowstreet Capital Limited Partnership purchased a new position in shares of Definitive Healthcare in the second quarter valued at $4,247,000. Inspire Investing LLC grew its holdings in Definitive Healthcare by 505.7% during the 4th quarter. Inspire Investing LLC now owns 698,967 shares of the company’s stock valued at $2,006,000 after purchasing an additional 583,562 shares in the last quarter. Millennium Management LLC increased its stake in Definitive Healthcare by 230.9% during the 4th quarter. Millennium Management LLC now owns 332,087 shares of the company’s stock worth $953,000 after buying an additional 231,743 shares during the period. Finally, Jane Street Group LLC increased its stake in Definitive Healthcare by 212.4% during the 2nd quarter. Jane Street Group LLC now owns 328,410 shares of the company’s stock worth $1,281,000 after buying an additional 223,296 shares during the period. 98.67% of the stock is currently owned by hedge funds and other institutional investors.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.